News & Events

The Firm represented Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC as the dealer managers in connection with a modified “Dutch auction” tender offer by Amgen Inc. for up to $10 billion of shares of its common stock. The tender offer expired on March 5, 2018 and settlement for the tender offer occurred on March 8, 2018. At settlement of the tender offer, the company purchased 52,083,333 shares of its common stock at a purchase price of $192 per share, for a total cost of approximately $10 billion, excluding fees and expenses related to the tender offer. The repurchased shares represented approximately 7.2% of the shares outstanding.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

The Simpson Thacher team for the tender offer included John D. Lobrano and Clark Warthen (Capital Markets); and Jonathan Cantor and Nicole Humphrey (Tax).